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Abstract
Background:  Monitoring of antiplatelet therapy in patients at cardiovascular risk is difficult
because existing platelet function tests are too sophisticated for clinical routine. The whole blood
TEG® Platelet Mapping™ assay measures clot strength as maximal amplitude (MA) and enables for
quantification of platelet function, including the contribution of the adenosine diphosphate (ADP)
and thromboxane A2 (TxA2) receptors to clot formation.
Methods: In 43 healthy blood donors, the analytical (CVa) and inter-individual variability (CVg) of
the TEG® Platelet Mapping™ assay were determined together with platelet receptor inhibition in
response to arachidonic acid (AA) and ADP.
Results: The CVa of the assay for maximal platelet contribution to clot strength (MAThrombin) was
3.5%, for the fibrin contribution to clot strength (MAFibrin) 5.2%, for MAAA 4.5% and for MAADP it was
6.6%. The MAThrombin CVg was 2.8%, MAFibrin 4.7%, MAAA 6.6% and for MAADP it was 26.2%. Females
had a higher MAThrombin compared to males (62.8 vs. 58.4 mm, p = 0.005). The platelet TxA2
receptor inhibition was 1.2% (range 0–10%) and lower than for the ADP receptor (18.6% (0–58%);
p < 0.0001).
Conclusion: The high variability in ADP receptor inhibition may explain both the differences in
response to ADP receptor inhibitor therapy and why major bleeding sometimes develops during
surgery in patients not treated with ADP receptor inhibitors. An analytical variation of ~5 % for
the TEG® enables, however, for routine monitoring of the variability in ADP receptor inhibition
and of antiplatelet therapy.
Background
Antiplatelet therapy is important for cardiovascular medi-
cine. The efficacy of aspirin in both primary and second-
ary prevention of myocardial infarction and stroke and
hence cardiovascular death is established [1,2] and the
addition of a platelet adenosine diphosphate (ADP)
receptor inhibitor, clopidogrel, further reduces these risks
[3,4]. Yet, platelet function tests (PFT) demonstrate that
subgroups of patients fail to develop the anticipated
antiplatelet effect of aspirin and/or clopidogrel [5,6]. The
PFT are, however, not applicable for routine purposes and
hence for clinical monitoring of antiplatelet therapy [7].
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The whole blood Thrombelastograph (TEG®) Platelet
Mapping™ assay measures clot strength, maximal ampli-
tude (MA), reflecting maximal platelet function, and
detects the reduction in platelet function, presented as
percentage inhibition, by both aspirin [8] and clopidog-
rel. This study evaluated the analytical (CVa) and inter-
individual (CVg) variation of the assay and the platelet
aggregation response, expressed as inhibition, to arachi-
donic acid (AA), representing a measure of the cyclooxy-
genase-1 (COX-1) activity, and to ADP in healthy blood
donors.
Methods
The study was in accordance with the Helsinki 2 Declara-
tion and the participants provided informed consent prior
to any study related activity. Forty-three Danish blood
donors, not taking any medication 10 days prior to the
investigation were included in the study. Blood was
drawn in citrate (9 volumes of blood into 1 volume of
0.129 M citrate, Vacutainer system, BD Biosciences, Ply-
moth, UK) and into heparin (17 IU/ml blood, Vacutainer
system, BD Biosciences, Plymoth, UK).
Thrombelastography
The TEG® Platelet Mapping™ assay (Haemoscope Corpo-
ration, Niles, Illinois, US) relies on evaluation of clot
strength to enable a quantitative analysis of platelet func-
tion. The maximal haemostatic activity is measured by a
kaolin activated whole blood sample treated with citrate.
The following measurements are performed with heparin
to eliminate thrombin activity: Reptilase and Factor XIII
(Activator F) generate a cross-linked fibrin clot to isolate
the fibrin contribution to the clot strength [9]. The contri-
bution of the ADP or ThromboxaneA2 (TxA2) receptors to
the clot formation is provided by the addition of ADP or
AA.
Blood was analyzed according to instructions (Haemo-
scope Corporation. TEG Guide to Platelet Mapping. Mon-
itor anti-platelet therapy, 2004). Both analyzer (series
5000) and the reagents were from Haemoscope Corpora-
tion.
For maximal clot strength (MAThrombin) one milliliter of cit-
rate-stabilized blood was transferred to a vial containing
kaolin and mixed by inversion. Kaolin activated blood
(340 μl) was added to a TEG® cup containing 20 μl of 0.2
M CaCl2. To generate a whole-blood fibrin cross-linked
clot, representing only the fibrin contribution included in
the clot strength measurement, heparinized blood (360
μl) was transferred to a TEG® cup containing 10 μl Activa-
tor F; MAFibrin (Fig. 1). The contribution of the P2Y12
receptor, or the COX-1 pathway, to the clot formation is
assessed by the addition of ADP or AA. Therefore, AA and
ADP, respectively, are added to Activator F to measure the
degree of ADP receptor and thromboxane A2 induced
platelet aggregation. Heparinized blood (360 μl) was
added to a TEG® cup in the presence of the Activator F and
agonist, 10 μl ADP (2 μM, final concentration) yielding
MAADP or 10 μl AA (1 mM, final concentration) for the
MAAA. The platelet inhibition in response to the agonist is
calculated from platelet aggregation: [(MAADP - MAFibrin)/
(MAThrombin - MAFibrin) × 100] and % inhibition = (100% -
% aggregation).
Statistical analysis
The coefficient of variation for CVa and CVg was calculated
for MAThrombin, MAFibrin, MAAA and MAADP[10]. Data are pre-
sented as mean ± SD or as mean with range. Comparisons
were made by Wilcoxon rank sum tests and a p-value <
0.05 was considered statistically significant.
Results
The MAThrombin was 60.9 ± 5.3 mm (Table 1). When com-
paring genders, females had both the higher MAThrombin
and MAFibrin (62.8 vs.58.3 mm, p = 0.005 and 8.1 vs. 6.6
mm; p = 0.035, respectively). The platelet aggregation in
response to AA, expressed as the percentage of natural
inhibition of the TxA2 receptor, varied between 0 and
10% with an average of 1.2%. The platelet aggregation in
response to ADP, expressed as the percentage of natural
inhibition of the ADP receptor, varied between 0 and 58%
with an average of 18.6% being higher than for the TxA2
receptor, p < 0.0001. No significant difference was, how-
ever, found between genders with regard to inhibition of
the TxA2 (1.3 vs. 1.1%, p = 0.71) or ADP receptors (18.2
vs. 19.4%, p = 0.41).
The CVa values were 3.5% for MAThrombin, for MAFibrin it was
5.2%, for MAADP 6.6 %, and for MAAA 4.5%. The CVg for
MAThrombin was 2.8%, for MAFibrin it was 4.7% and for MAAA
6.6%, whereas the CVg for the MAADP was 26.2% (Table 2).
Discussion
The analytical variation (CVa) of the TEG® Platelet Map-
ping™ assay was ~5% in alignment with the findings of
Craft et al. [9] investigating 120 subjects and concluding
that this point of care assay makes it possible to conduct
large scale comparative studies on the degree of platelet
inhibition and patient outcome. Conventional aggregom-
etry, representing the current "gold standard" for measur-
ing platelet reactivity to ADP and AA and to assess the
effect of antiplatelet agents, is valuable for the experienced
and specialised laboratory.
The low analytical variation of the TEG® Platelet Map-
ping™ assay found in this study may reflect the use of
whole blood, obviating pre-analytical and analytic factors
such as platelet count and size, preparation of platelet rich
plasma (PRP), including centrifugation steps [11,12]. TheThrombosis Journal 2007, 5:3 http://www.thrombosisjournal.com/content/5/1/3
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platelet function analyzer 100 (PFA-100), likely the most
widely used point of care test for platelet inhibition, meas-
ures the time required for blood under simulated high
shear flow to occlude a collagen/epinephrine or a colla-
gen/ADP-coated aperture inserted in a plastic membrane.
The PFA-100 is valuable for evaluation of platelet inhibi-
tion due to AA, while platelet inhibition due to ADP
remains unsolved [13,14]. Duplicate testing, however, is a
requirement to obtain reliable results [14].
The thrombin induced clot formation, MAThrombin, repre-
sents the maximum uninhibited platelet function and was
within the normal reference values of 51 to 69 mm, as
described by the manufacturer, except for one donor hav-
ing a MAThrombin of 70.1 mm. A gender difference, with
females having the higher MAThrombin, suggests that females
are better protected against bleeding than males [15].
The TEG® Platelet Mapping™ assay enables for evaluation
of the respective contribution of the ADP and the TxA2
receptors to clot formation by the addition of the appro-
priate agonists.
The response in platelet aggregation due to the agonist AA
presented as the percentage inhibition of the platelet TxA2
receptor was less than 2% with no difference between gen-
der and lower than the reported value of 14% [8]. How-
ever, Gurbel et al. [8] investigated only 6 donors, whereas
43 donors were evaluated in the present study. Genetic
polymorphism in the platelet receptors has been reported
and we cannot exclude that other differences exist
between the two populations.
The variation in platelet aggregation due to ADP stimula-
tion, evaluated as the percentage ADP receptor inhibition,
Table 1: TEG® Platelet Mapping™ assay variables (see text) and percent platelet receptor inhibition for healthy blood donors.
All donors Females (n = 27) Males (n = 16)
MAThrombin 60.9 (4.5) 62.8 (5.3) 58.4 (5.4) *
MAFibrin 7.5 (2.7) 8.1 (2.8) 6.6 (2.2) *
MAADP 51.1 (8.1) 52.7 (7.8) 48.5 (8.1)
MAAA 64.6 (4.7) 66.1 (4.5) 62.5 (4.3)
% ADP RIa 18.6 (0–58.1) 18.2 (0–58.1) 19.4 (0–37.5)
% TxA2 RIa 1.2 (0–10.1) 1.3 (0–9.8) 1.1 (0–10.1)
Values are mean and SD or range
aRI = receptor inhibition
*Comparison between female and male donors, p < 0.05
Profiles of the TEG® Platelet Mapping™ assay parameters MAThrombin, MAADP/AA, and MAFibrin Figure 1
Profiles of the TEG® Platelet Mapping™ assay parameters MAThrombin, MAADP/AA, and MAFibrin.Thrombosis Journal 2007, 5:3 http://www.thrombosisjournal.com/content/5/1/3
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was almost 60% and independent of gender. The inter-
individual difference could be attributed to differences in
the ADP receptors and to the number of receptors the
individual possesses, varying the levels of ADP release, or
platelet activation via alternative pathways [6]. Differ-
ences in response to ADP receptor inhibitors between
individuals have been demonstrated [16,17] and may, at
least in part, be due to the difference in platelet reactivity.
Patients treated with the ADP receptor inhibitor clopidog-
rel are at risk of major bleeding during surgery [18]. Due
to the high variation between the donors in ADP receptor
inhibition, those with a high natural inhibition may be at
risk of developing excessive bleeding during surgery.
The TEG® Platelet Mapping™ assay enables relating the
percent platelet inhibition to the individual's maximum
uninhibited platelet function. Hereby the individual
response to antiplatelet therapy is related to their own
maximum uninhibited platelet function of potential ther-
apeutic consequence. A MAThrombin value above the normal
reference range is associated with an increased risk of
thrombotic complications and ischemic events [19,20]
implying that individual antiplatelet therapy may reduce
the risk of recurrent events and also prevent the risk of
bleeding.
Only Caucasian blood donors were studied and the utility
of the assay for patients at cardiovascular risk remains to
be evaluated. Natural platelet receptor inhibition was
investigated and, therefore, the validity of the assay for
monitoring patients in antiplatelet therapy was not
assessed.
Conclusion
An analytical variation of ~5 % for the TEG® Platelet Map-
ping™ assay enables for routine monitoring of antiplatelet
therapy in patients at cardiovascular risk. The high natural
ADP receptor variability may, in part, explain differences
in response to clopidogrel therapy. Furthermore, the high
variability in natural ADP receptor inhibition may explain
why unexpected bleeding can develop during surgery in
some patients as although they are not treated with ADP
receptor inhibitors.
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